The clinical trial, conducted by researchers at the NYU Langone Health and Baptist Health/Jacksonville Orthopaedic Institute, found that an orally absorbed tablet containing cannabidiol (CBD) “safely managed pain after minimally invasive rotator cuff surgery, and did not produce side effects sometimes associated with CBD use, such as nausea, anxiety, and liver toxicity.”

Researchers randomly sorted 99 participants across the two study sites, NYU Langone and Baptist Health in Jacksonville, “between the ages of 18 and 75 into a placebo group and a group receiving oral-absorbed CBD,” who were “prescribed a low dose of Percocet, instructed to wean off the narcotic as soon as possible, and to take the placebo/CBD 3 times a day for 14 days after the surgery.”

“On the first day after surgery, patients receiving CBD experienced on average 23 percent less pain as measured by the visual analog scale (VAS) pain score compared to patients receiving the placebo, highlighting that in patients with moderate pain, CBD may render a significant benefit,” the researchers wrote in their analysis. “On both the first and second days after surgery, patients receiving CBD reported 22 to 25 percent greater satisfaction with pain control compared to those receiving placebo. Patients who received 50mg of CBD had lower levels of pain and greater satisfaction than patients receiving placebo. No major side effects were reported.”

Results of the study were presented at the American Academy of Orthopaedic Surgeons 2022 Annual Meeting, Chicago in March.

On Monday, TR Processing LLC revealed that it served as the CBD supplier for the clinical trial––an announcement that was accompanied by a presidential endorsement.

In a press release, TR Processing said that Clinton has been “following the study through the Clinton Foundation.”

According to the former President, the study is an integral part in efforts to curb opioid addiction and dependency in the United States. TR Processing, citing data from the Centers for Disease Control and Prevention, noted in the announcement that “more than 100,000 Americans died of drug overdoses in 2021 and one million lives were lost to overdoses in the past two decades,” an “epidemic [that] costs the U.S. more than $1 trillion a year.”

“The Clinton Foundation has worked for years to reduce opioid addiction and deaths. To succeed, we need non-addictive alternatives to pain management,” Clinton said in a statement. “The results of the trial conducted by NYU Langone, with TRP’s CBD ingredient, are very encouraging and I’m eager to see the results of the next round.”

Michael J. Alaia, associate professor in the NYU Department of Orthopedic Surgery and a lead researcher on the study, said there “is an urgent need for viable alternatives for pain management, and our study presents this form of CBD as a promising tool after arthroscopic rotator cuff repair.”

“It could be a new, inexpensive approach for delivering pain relief, and without the side effects of anti-inflammatory drugs like NSAIDs and addiction risks linked to opiates. Additionally, CBD has the benefit of pain relief without the psychotropic effects associated with THC or marijuana,” Alaia said.

Chris Kanaley, chief strategy officer at TR Processing, said that the company is “committed to supporting the study and responsible commercialization of isolated cannabinoids, including CBD.”

“Tackling opioid abuse and addiction through the development of safer pain management alternatives is the first of many potential uses of our unique processing platform, and we are enthusiastic about the future. Our work has tremendous potential to become precision medicine at its best,” Kanaley said.